Full-Time

Quality Program Management Supervisor

Quality Program Management

Curia

Curia

1,001-5,000 employees

End-to-end drug development and manufacturing

No salary listed

Albuquerque, NM, USA

In Person

Bachelor's

Category
Biology & Biotech (1)

Get referred to Curia

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Science, Chemistry, Biology or related field of study
  • Minimum of three (3) years in Quality Assurance or Regulatory Compliance Management
  • Minimum of two (2) years in a leadership role
  • Must pass a background check
  • Must pass a drug screen
Responsibilities
  • Supervise and provide guidance to the QA batch record review and product disposition team
  • Support client Quality relationships through effective communication and timely deliverables
  • Review and assist in the disposition of executed Batch Records (Clinical, Commercial, & Media Fills) and collaborate with cross-functional teams to address review comments
  • Maintain the record review planner to track and monitor the stages of the batch disposition process, including manufacturing and quality reviews and quality disposition processes
  • Support efforts to monitor and improve batch record review and disposition cycle times
  • Assist in tracking metrics for the review and disposition process and provide input for monthly performance analysis
  • Oversee Disposition timelines and support client calls related to Disposition schedules and delays
  • Ensure timely responses to client comments on Batch Records
  • Coordinate with QC labs, external testing, and the deviations team to ensure all deliverables are completed on time to meet supply commitments
  • Coordinate shipments with the Warehouse (including Q Ships & Release Shipments)
  • Participate in critical DEV review meetings and provide quality input as needed
  • Contribute to the preparation and presentation of weekly and monthly metrics for leadership
  • Assist in developing batch record review training materials for Quality and Production teams
  • Review and provide input on SOPs related to the functional area
  • Support internal, client, and regulatory audits for batch record reviews
  • Identify process improvements and assist in their implementation
  • Provide support in other QA areas as assigned by QA Management.
  • Read/interpret SOPs to ensure compliance
  • Maintain up to date trainings
  • Other duties as assigned
Desired Qualifications
  • Minimum of three (3) years in an aseptic/sterile product facility experience (preferred)
  • Knowledge in current regulations (21 CFR, Annex 1 etc), preferred

Curia is a contract development and manufacturing organization (CDMO) that partners with pharmaceutical and biotech companies to move medical breakthroughs from concept to market. It provides end-to-end services across the drug development lifecycle, including early research, method development and validation, preformulation, material science, solid-state chemistry, and package device testing. Revenue comes from service contracts for specialized capabilities and expertise, with clients ranging from small startups to large pharma. Curia also collaborates with industry leaders to advance continuous flow development and manufacturing programs. The company differentiates itself through flexible and scalable solutions, deep scientific expertise, and state-of-the-art technology that help clients accelerate development timelines while navigating discovery to commercialization. Its goal is to enable efficient, reliable progression of drug candidates from conception through to market approval.

Company Size

1,001-5,000

Company Stage

Debt Financing

Total Funding

$132M

Headquarters

Albany, New York

Founded

1991

Get referred to Curia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Curia expanded Glasgow sterile drug product capacity in March 2026.
  • Curia completed a $4 million sterile API upgrade in Valladolid in October 2025.
  • Curia won a 2025 CDMO Leadership Award in Global Biologics.

What critics are saying

  • Curia is closing Burlington in 2026 and cutting 81 jobs.
  • Curia is working on an out-of-court restructuring with private credit lenders.
  • Asset sales like Pace’s New Jersey lab purchase signal continued portfolio shrinkage.

What makes Curia unique

  • Curia spans discovery through commercial manufacturing across small molecules and biologics.
  • Curia manufactures mRNA and self-replicating RNA, including Replicate Bioscience’s RBI-4000.
  • Curia runs 20+ global sites with sterile fill-finish and cell-line development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Carlyle
Jan 30th, 2026
AMRI Announces Completion of Acquisition by The Carlyle Group and GTCR | Carlyle

ALBANY, N.Y. – Albany Molecular Research, Inc. (NASDAQ:AMRI), a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life for more than 25 years, today announced the completion of its previously announced acquisition by affiliates of The Carlyle Group (“Carlyle”) and affiliates of GTCR LLC (“GTCR”). President and Chief Executive Officer William S. Marth will continue to lead AMRI.

BERNAMA
May 10th, 2024
BIOLOGICS SYMPOSIUM: CURIA, CARTERRA PARTNER TO ADVANCE BIOTECH RESEARCH IN PACIFIC NORTHWEST

KUALA LUMPUR, May 10 (Bernama) - Curia, a contract research, development and manufacturing organisation (CDMO) has announced a partnership with Carterra Inc in hosting a high-throughput biologics symposium slated for May 31, in Seattle, Washington.

PharmiWeb
Mar 14th, 2024
Pace® Life Sciences Acquires New Jersey Laboratory From Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network

Pakistan Press International
Feb 23rd, 2024
Curia Appoints Steve Lavezoli as Vice President, Biologics

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) - Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.

Cameroon Online News
Feb 5th, 2024
Curia Receives 2024 CDMO Leadership Award

Curia was awarded based on the feedback of respondents in the Small Pharma category.